Major Administrative Leadership Positions

Local

1995-1996	Biostatistical Consulting Lab Co-Director	Dept. of Biostatistics, Medical College of Virginia, Virginia Commonwealth University
2002-2009	Associate Program Director / Co-Director	National Institutes of Health (NIH)/National Cancer Institute (NCI) Children's Oncology Group[1] (COG) Statistics and Data Center, Univ of Florida
2009-present	Director of Biostatistics	Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School
2009-2019	Director, Clinical and Translational Investigation Program (CTIP)	Division of Hematology/Oncology, Boston Children's Hospital, Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School
2012-present	Faculty Director, Survey and Qualitative Methods Core	Dana-Farber / Harvard Cancer Center
2012-present	Co-Director, Research and Data Analysis Core	Partnership of the University of Massachusetts/Boston and Dana-Farber Cancer Institute
2022-present	Director, Biostatistics Core	Dana-Farber/Harvard Cancer Center Glioma SPORE

National and International

(Each COG[1] disease committee is a distinct, scientific working group with its own long term strategic plan. Dr. London was funded full-time by COG[1] grants for 12 years, and 30% effort for five years after moving to Boston Children's Hospital, thus her leadership on multiple COG[1] scientific and administrative committees.)

1998-present	Scientific Steering Committee Member	Children's Oncology Group (COG[1]) Neuroblastoma Committee

[1] The Children's Oncology Group is not a professional society, it is the only pediatric cancer cooperative group in the country, funded by the NIH / NCI via U10 grants (since ~1975). >220 treating institutions in North America, Australia, New Zealand, and Switzerland comprise the COG, with >5,000 members (oncologists, surgeons, pathologists, nurses, CRAs, statisticians). Half of all children with cancer in North America will enroll on at least one COG study. At any given time, COG is conducting over 100 clinical or biological trials, trials that set the standard of care. The COG Statistics and Data Center provides the infrastructure, including study design, data collection, interim monitoring, statistical analysis, and manuscripts. COG is organized by permanent scientific working 'committees' (led by an Executive committee) to conduct national clinical

2008-2009	Data Safety Monitoring Board 2008-2009	Neurofibromatosis Consortium Member
2009-2015	Data Safety Monitoring Board	Division of Microbiology and Infectious Diseases (DMID) Protocol 07-0012: Randomized Trial of Azithromycin versus Doxycycline for genital Chlamydial infection in females in youth correctional facilities
	2009-2015	Member
2011-2018	International Neuroblastoma Response Criteria Working Group	National Cancer Institute
	2011-2018	Executive Committee Member
2019-present	Data Safety Monitoring Board	"RQ 092 (Miransertib) in Subjects with PIK3CA-related Overgrowth Spectrum and Proteus Syndrome". Sponsor: Merck (originally ArQule, Inc.)
	2019- present	Member
2019-present	Data Safety Monitoring Board	Jubilant Draximage trial of metaiodobenzylguanidine (MIGB) in neuroblastoma
	2019- present	Member
2020-present	The INRG Version 2 Task Force	The International Neuroblastoma Risk Groups Project
	2020- present	Co-Chair

Professional Societies

1987-1992	SAS Users' Groups International	
	1987-1992	Member
	1990, 1991, 1992	Session Coordinator
	1991, 1992	Section Chair, Northeast SAS Users' Group Pharmaceutical Section
1990-present	American Statistical Association	
	1990-1996	Member Member, Local Arrangements Committee for Eastern North American Region (ENAR) of American Statistical Association (ASA)
	1999	Session Chair, Joint Statistical Meetings

Training Grants and Mentored Trainee Grants

2009-2010 Using item response theory to improve children's quality of life assessment
NIH 1K23HD057146-01A2
Mentor of I-Chan Huang
The major goal is to train Dr. Huang to become an independent researcher in the area of children's health-related quality of life (HRQOL) assessment, which measures physical and psychosocial functioning, and its clinical application.

2014-2019 Research Training in Pediatric Oncology
NIH 2T32CA136432-06A1
Faculty
The major goal is to train physicians who will be the future academic leaders in basic and/or clinical pediatric oncology research and who will work to reduce the burden of cancer in the pediatric population.

Submitted 11/2021 Characterization and validation of circulating tumor DNA (ctDNA) as a clinical biomarker in Ewing sarcoma
NIH / K08
Mentor of David Shulman
The major goal is to provide mentorship to Dr. Shulman as he develops statistical skills. Dr. London's mentorship for this grant focuses on survival analysis and regression modeling for ctDNA biomarker validation.
SRG Action: Impact/Priority Score: 27 (not funded)

Current Unfunded Projects

2010-present U.S. News and World Report – Best Children's Hospitals survey
Role: Statistician
The major goal of this project was to accurately and reproducibly answer questions on the survey on an annual basis, including the 5-year pediatric cancer survival rates and number of oncology patients on clinical trials.

2012-present Datamart: The Pediatric Patient Informatics Platform (*PPIP*)
Role: PI
The major goal of this project is to create and maintain a datamart to serve as a local and national resource. The *PPIP* datamart integrates patient data (clinical, outcome, genomics, specimens) and protocol data (PI, accrual goal, activation date) from disparate sources at BCH and DFCI, to facilitate research, operations and safety reporting, and strategic planning.

Report of Local Teaching and Training

Teaching of Students in Courses

2006-2008	Science of Clinical and Translational Research Course	University of Florida College of Medicine
	Medical students, residents, fellows, and faculty members	Annual 1 hr lecture
2007	Writing the statistical section of a grant	University of Florida, Division of Epidemiology and Health Policy Research
	Epidemiology graduate students	1 hr lecture

Formal Teaching of Residents, Clinical Fellows and Research Fellows (post-docs)

2005-2009	Evaluating experimental design and statistics of research publications	University of Florida, Dept of Surgery
	2nd and 3rd year surgery residents	Annual 1-hour lecture
2009-2017	Data Blitz	Dana-Farber Cancer Institute/ Boston Children's Hospital, Division of Hematology/Oncology
	Fellows and faculty	Annual 5-min lecture, 5 min Q&A
2010-present	Consolidation course	Dana-Farber Cancer Institute/Boston Children's Hospital, Division of Pediatric Hematology/Oncology
	Fellows and faculty	Annually: two 1-hour lectures
2017	Innovative Phase 1 Study Designs	Dana-Farber Cancer Institute/Boston Children's Hospital, Division of Pediatric Hematology/Oncology
	Fellows, faculty, and staff of the Experimental Therapeutics Program	1-hour lecture

Research Supervisory and Training Responsibilities

2001-2008	Advised/instructed a statistics department graduate assistant in the design and statistical analysis of the Children's Oncology Group clinical trials	Mentorship 3 days a week for 1 year
2009-present	Train and educate statisticians of the Biostatistics Program: authorship on scholarly works for peer-reviewed publication	Mentorship 4-5 hours per week
2009-present	Train and educate residents, fellows, and junior faculty regarding the design and conduct of clinical research	Mentorship 2-4 hours per week

Formally Mentored Harvard Medical, Dental, and Graduate Students

deAlarcon P, Chauvenet A. Risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate and high risk Hodgkin lymphoma: The results of P9425. *Blood* 2009 Sep 3;114(10):2051-9. PMID: 19584400 PMCID: PMC2744567.

71. Lagmay J**, **London WB**, Gross T, Termuhlen A, Sullivan N, Axel A, Mundy B, Ranalli M, Canner J, McGrady P**, Hall B. Prognostic significance of interleukin-6 single nucleotide polymorphism genotypes in neuroblastoma: *rs1800795* (promoter) and *rs8192284* (receptor). *Clinical Cancer Research* 2009 Aug 15;15(16):5235-9. PMIC: 19671870 PMCID: PMC2740837.

72. Combaret V, Hogarty MD, **London WB**, McGrady P**, Iacono I, Brejon S, Swerts K, Noguera R, Gross N, Rousseau R, Puisieux A. Influence of neuroblastoma stage on serum-based detection of *MYCN* amplification. *Pediatric Blood and Cancer* 2009 Sep;53(3):329-31. PMID: 19301388 PMCID: PMC2857568.

73. Okamatsu C, **London WB**, Naranjo A**, Hogarty MD, Gastier-Foster JM, Look AT, LaQuaglia M, Maris JM, Cohn SL, Matthay KK, Seeger RC, Saji T, and Shimada H. Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG[1]. *Pediatric Blood and Cancer*. 2009 Oct;53(4):563-9. PMID: 19530234 PMCID: PMC2730988.

74. Bray I, Bryan K, Prenter S, Buckley PG, Foley NH, Murphy DM, Alcock L, Mestdagh P, Vandesompele J, Speleman F, **London WB**, McGrady PW**, Higgins DG, O'Meara A, O'Sullivan M, Stallings RL. Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival. *PloS One*. 2009 Nov 16;4(11):e7850.PMID: 19924232. PMCID: PMC2773120

75. **London WB**, Sondel P, Gilman AL, Ozkaynak F, Kreissman S, Buxton A**, Chen H, Matthay KK, Cohn SL, Maris JM, Yu AL. Success of chimeric anti-GD2 antibody+GM-CSF+IL2 immunotherapy in high-risk neuroblastoma (NB) in first response: a critical appraisal. *Pediatr. Blood Cancer.* 2009 Sept; 53(5):708-708. _____

76. Katzenstein HM, Chang KW, Krailo M, Chen Z, Bowman LC, Finegold MJ, Rowland J, Greffe B, Reynolds M, Newman K, Womer R, Castleberry RP, Pappo A, **London WB,** Malogolowkin M. Amifostine does not prevent platinum-induced hearing loss associated with the treatment of children with hepatoblastoma. A report of the Intergroup hepatoblastoma study P9645 as part of the Children's Oncology Group. 2009. *Cancer* 2009 Dec 15;115(24):5828-5835. PMID: 19813275 PMCID: PMC2795100

77. Devidas M, **London WB**, Anderson JR. The use of central laboratories and remote electronic data capture to risk–adjust therapy for pediatric acute lymphoblastic leukemia and neuroblastoma. *Seminars in Oncology*. 2010 Feb 37(1):53-59. PMID: 20172365 PMCID: PMC2843557

78. Bensimhon P, Villablanca JG, Sender LS, Matthay KK, Park JR, Seeger R, **London WB**, Yap JS**, Kreissman SG. Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: A report from the Children's Oncology Group. *Pediatric Blood and Cancer*. 2010 Apr;54(4):596-602. PMID: 20049927 PMCID: PMC2905158.

79. **London WB**, Frantz FN, Campbell LA, Seeger RC, Brumback BA, Cohn SL, Matthay KK,

96. Villablanca JG, **London WB**, Naranjo A**, McGrady P**, Ames MM, Reid JM, McGovern RM, Buhrow SA, Jackson H, Stranzinger E, Kitchen BJ, Sondel PM, Parisi MT, Shulkin B,Yanik GA, Cohn SL, Reynolds CP. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: A report from the Children's Oncology Group. *Clinical Cancer Research*. 2011 Nov. 1;17(21)6858-66. Epub 2011 Sept. 9. Doi:10.1158/1078-0432.CCR-11-0995 PMID: 21908574 PMCID: PMC3207022.

97. Taggart DR**, **London WB**, Schmidt ML, DuBois SG**, Monclair T, Nakagawara A, De Bernardi B, Ambros P, Pearson AD, Cohn SL, Matthay KK. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age. *Journal of Clinical Oncology.* 2011 Nov. 20;29(33):4358-64. Epub 2011 Oct. 3. Doi:10.1200/JCO.2011.35.9570 PMID: 21969516 PMCID: PMC3221520.

98. Light JE**, Koyama H, Minturn JE, Ho R, Simpson AM, Iyer R, Mangino JL, Kolla V, **London WB**, Brodeur GM. Clinical significance of NTRK family gene expression in neuroblastomas. *Pediatr Blood Cancer.* 2012 Aug;59(2):226-32. Doi: 10.1002/pbc.23343. Epub 2011Oct 11. PMID: 2199026

99. Park JR, Scott JR, Stewart CF, **London WB**, Naranjo A**, Santana VM, Shaw PJ, Cohn SL, Matthay KK. A pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study. *J Clin Oncol.* 2011 Nov 20;29(33):4351-7. Epub 2011 Oct 17. PMID: 22010014 PMCID: PMC3221519.

100. De Preter K*, Mestdagh P*, Vermeulen J*, Zeka F, Naranjo A**, Bray I, Castel V, Chen C, Drozynska E, Eggert A, Hogarty MD, Iżycka E, **London WB**, Noguera R, Piqueras M, Bryan K, Schowe B, van Sluis P, Molenaar JJ, Schramm A, Schulte JH, Stallings RL, Versteeg R, Laureys G, Van Roy N, Speleman F, Vandesompele J. miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. *Clinical Cancer Research*. 2011 Dec. 15;17(24)7684-92. Epub 2011 Oct. 26. Doi10,1158/1078-0432.CCR-11-0610.: [* = share first authorship] PMID: 22031065 PMCID: PMC4008338

101. Angelini P**, **London WB**, Cohn SL, Pearson AD, Matthay KK, Monclair T, Ambros PF, Shimada H, Leuschner I, Peuchmaur M, Irwin MS, Baruchel S. *Eur J Cancer.* 2012 May;48(8):1185-91. Epub 2011 Dec 1. PMID: 22137163

102. George RE, Perez-Atayde AR, Yao X, **London WB**, Shamberger RC, Neuberg D, Diller L. Tumor histology during induction therapy in patients with high-risk neuroblastoma. *Pediatric Blood & Cancer*. 2011 Dec. 11. [Epub ahead of print] doi:10.1002/pbc.24013 PMID: 22162143

103. Fletcher JI, Gherardi S, Murray J, Burkhart CA, Russell A, Valli E, Smith J, Oberthuer A, Ashton LJ, **London WB**, Marshall GM, Norris MD, Perini G, Haber M. *N-Myc* regulates expression of the detoxifying enzyme glutathione transferase GSTP1, a marker of poor outcome in neuroblastoma. *Cancer Research*. 2012 Feb 15;72(4):845-53. Epub 2011 Dec 27. PMID: 22202125

104. Koyama H, Zhuang T, Light JE, Kolla V, Higashi M, McGrady PW**, **London WB**, Brodeur GM. Mechanisms of chd5 inactivation in neuroblastomas. *Clin Cancer Res.* 2012 Mar 15;18(6):1588-97. Epub 2012 Jan 31. PMID: 22294723 PMCID: PMC3306487.

Doi: 10.1038/ng.2529. Epub 2013 Jan 20. PMID: 23334666 PMCID: PMC3682833

121. Seif AE, Naranjo A**, Baker DL, Bunin NJ, Kletzel M, Kretschmar CS, Maris JM, McGrady PW**, von Allmen D, Cohn SL, **London WB,** Park, JR, Diller LS, Grupp S. A Pilot Study of Tandem High Dose Chemotherapy with Stem Cell Rescue as Consolidation for High Risk Neuroblastoma: Children's Oncology Group study ANBL00P1. *Bone Marrow Transplantation*. 2013 Jan 21. Doi: 10.1038/bmt.2012.276. [Epub ahead of print] PMID: 23334272. PMCID: PMC3638062

122. Yanik GA, Parisi MT, Shulkin BL, Naranjo A**, Kreissman SG, **London WB**, Villablanca JG, Maris JM, Park JR, Cohn SL, McGrady P**, Matthay KK. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group. *J Nucl Med.* 2013 Apr;54(4):541-8. Doi: 10.2967/jnumed.112.112334. Epub 2013 Feb 25. PMID: 23440556

123. Kirby C, Ambros PF, Billiter D, **London WB**, Mendonca E, Monclair T, Pearson AD, Cohn SL, Volchenboum SL. Development of an open-source, flexible framework for complex inter-institutional disparate data sharing and collaboration. *AMIA Summits Transl Sci Proc*. 2013 Mar 18;2013:103. eCollection 2013. PMID: 24303312.

124. Robison NJ**, Prabhu SP, Sun P, Chi SN, Kieran MW, Manley PE, Cohen LE, Goumnerova L, Smith ER, Scott RM, **London WB**, Ullrich NJ. Predictors of neoplastic disease in children with isolated pituitary stalk thickening. *Pediatr Blood Cancer*. 2013 Oct;60(10):1630-5. Doi: 10.1002/pbc.24577. Epub 2013 May 14. PMID: 23670879

125. Kreissman SG, Seeger RC, Matthay KK, **London WB**, Sposto R, Grupp SA, Haas-Kogan DA, LaQuaglia M, Yu AL, Diller L, Buxton A**, Park JR, Cohn SL, Maris JM, Reynolds CP, Villablanca JG. Prospective Randomized Trial of Purged versus Non-Purged Peripheral Blood Stem Cell Transplant for High Risk Neuroblastoma. *Lancet Oncology* 2013 Sep;14(10):999-1008. Doi: 10.1016/S1470-2045(13)70309-7. Epub 2013 Jul 25. PMID: 23890779. PMCID: PMC3963485

- Audrey Evans Prize for the Outstanding Paper in Clinical Research, Advances in Neuroblastoma Research (ANR) 2008 meeting

126. Wang LL, Suganuma R, Ikegaki N, Tang X, Naranjo A**, McGrady P**, **London WB**, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Shimada H. Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group. *Cancer.* 2013 Oct 15;119(20):3718-26. Doi: 10.1002/cncr.28251. Epub 2013 Jul 30. PMID: 23901000

127. Mosse Y**, Deyell R, Berthold F, Nakagawara A, Ambros P, Monclair T, Cohn S, Pearson A, **London WB***, Matthay, KK*. Neuroblastoma in Older Children, Adolescents and Young Adults: A Report from the International Neuroblastoma Risk Group Project. *Pediatric Blood and Cancer*. 2014 Apr;61(4):627-35. Doi: 10.1002/pbc.24777. Epub 2013 Sep 13. PMID: 24038992. [* shared senior authorship]

128. Fox E, Mosse' YP, Meany HM, Gurney JG, Khanna G, Jackson HA, Gordon G, Shusterman S, Park JR, Cohn SL, Adamson PC, **London WB**, Maris JM, Balis FM. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A report from the

Children's Oncology Group (ANBL0621). *Pediatr Blood Cancer*. 2013 Jun;61(6):990-6. Doi: 10.1002/pbc.24900. Epub 2013 Dec 18. PMID: 24347462*

129. Landier W, Knight K, Wong FL, Lee J, Thomas O, Kim H, Kreissman SG, Schmidt ML, Chen L, **London WB**, Gurney JG, Bhatia S. Ototoxicity in Children with High-Risk Neuroblastoma – Prevalence, Risk Factors, and Concordance of Grading Scales: A Report from the Children's Oncology Group. *J Clin Oncol* 2014 Feb 20;32(6):527-34. Doi: 10.1200/JCO.2013.51.2038. Epub Jan 13. PMID: 24419114 PMCID: PMC3918536.

130. Bandopadhayay P**, Bergthold G, **London WB**, Goumnerova LC, Morales La Madrid A, Marcus K, Guo D**, Ullrich NJ, Robison NJ, Chi SN, Beroukhim R, Kieran MW, Manley PE. Long-term outcome of 4,040 children diagnosed with pediatric low-grade gliomas: An analysis of the Surveillance Epidemiology and End Results (SEER) database. *Pediatric Blood and Cancer* 2014 Jul;61(7):1173-9. Doi: 10.1002/pbc.24958. Epub 2014 Jan 30. PMID:24482038.

131. Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, **London WB**, Pytel P, Maclean KH, Cohn SL. Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system. *Mol Oncol*. 2014 May;8(3):669-78. Doi: 10.1016/j.molonc.2014.01.010. Epub 2014 Jan 31. PMID: 24560446. PMCID: PMC40046651

132. Pinto N, Gamazon ER, Antao N, Myers J, Stark AL, Konkashbaev A, Im HK, Diskin SJ, **London WB**, Ludeman SM, Maris JM, Cox NJ, Cohn SL, Dolan ME. Integrating Cell-Based and Clinical Genome-Wide Studies to Identify Genetic Variants Contributing to Treatment Failure in Neuroblastoma Patients. *Clinical Pharmacology & Therapeutics*. 2014 2014 Jun;95(6):644-52. Doi: 10.1038/clpt.2014.37. Epub 2014 Feb 18. PMID:24549002 PMCID: PMC4029857.

133. Morgenstern DA**, **London WB**, Stephens D, Volchenbaum S, Hero B, Di Cataldo A, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson ADJ, Irwin MS. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: a study from the International Neuroblastoma Risk Group (INRG) database. *J Clin Oncol* 2014 Apr 20;32(12):1228-35. Doi: 10.1200/JCO.2013.53.6342. Epub 2014 Mar 24. PMID:24663047.

134. Kesselheim JC, Sun P, Woolf AD, **London WB**, Boyer D. Balancing education and service in graduate medical education: Data from pediatric trainees and program directors. *Acad Med*. 2014 Apr;89(4):652-7. Doi: 10.1097/ACM.0000000000000174. PMID: 24556769.

135. Shahbazi J, Scarlett CJ, Norris MD, Liu B, Haber M, Tee AE, Carrier A, Biankin AV, **London WB**, Marshall GM, Lock RB, Liu T. Histone deacetylase 2 and N-Myc reduce p53 protein phosphorylation at serine 46 by repressing gene transcription of tumor protein 53-induced nuclear protein 1. Oncotarget. 2014 Jun 30;5(12):4257-68. PMID: 24952595

136. Meany HJ**, **London WB**, Ambros PF, Matthay KK, Monclair T, Simon T, Garaventa A, Berthold F, Nakagawara A, Cohn SL, Pearson AD, Park JR. Significance of clinical and biologic features in Stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. *Pediatric blood & cancer,* 2014 Nov;61(11):1932-9. Doi: 10.1002/pbc.25134. Epub 2014 Jul 7.

PMID: 25044743.

137. Vo KT**, Matthay KK, Neuhaus J, **London WB**, Hero B, Ambros PF, Nakagawara A, Miniati D, Wheeler K, Pearson AD, Cohn SL, DuBois SG. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol. 2014 Oct 1;32(28):3169-76. Doi: 10.1200/JCO.2014.56.1621. Epub 2014 Aug 25. PMID: 25154816

138. Teshiba R, Kawano S, Wang LL, He L, Naranjo A**, **London WB**, Seeger RC, Gastier-Foster JM, Look AT, Hogarty MD, Cohn SL, Maris JM, Park JR, Shimada H. Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index (MKI) in Neuroblastoma: A Report from the Children's Oncology Group. *Pediatric and Developmental Pathology* 2014 Nov-Dec;17(6):441-9. Doi: 10.2350/14-06-1505-OA.*1. E*pub 2014 Sep 10 PMID: 25207821 PMCID: PMC4340697

139. Hacein-Bey-Abina S, Pai SY, Gaspar HB, Armant M, Berry CC, Blanche S, Bleesing J, Blondeau J, de Boer H, Buckland KF, Caccavelli L, Cros G, De Oliveira S, Fernández KS, Guo D**, Harris CE, Hopkins G, Lehmann LE, Lim A, **London WB**, van der Loo JCM, Malani N, Male F, Malik P, Marinovic MA, McNicol AM, Moshous D, Neven B, Oleastro M, Picard C, Ritz J, Rivat C, Schambach A, Shaw KL, Sherman EA, Silberstein LE, Six E, Touzot F, Tsytsykova A, Xu-Bayford J, Baum C, Bushman FD, Fischer A, Kohn DB, Filipovich AH, Notarangelo LD, Cavazzana M, Williams DA, and Thrasher AJ. A Modified γ-Retrovirus Vector for X-Linked Severe Combined Immunodeficiency. *New England Journal of Medicine*. 2014 Oct 9:371(15): 1407-17. PMID: 25295500 PMCID: PMC4274995

- Distinguished Clinical Research Achievement Award from the Clinical Research Forum

140. Trippett TM, Schwartz CL, Guillerman RP, Gamis AS, Gardner S, Hogan S, **London WB**, Chen L, de Alarcon P. Ifosfamide and Vinorelbine is an Effective Reinduction regimen in Children with Refractory/Relapsed Hodgkin Lymphoma, AHOD00P1: A Children's Oncology Group Report. *Pediatric Blood and Cancer* 2015 Jan;62(1):60-4. Doi: 10.1002/pbc.25205. Epub 2014 Oct 12. PMID: 25308760.

141. Bona K**, **London WB**, Guo D**, Abel G, Lehmann L, Wolfe J. Prevalence and Impact of Financial Hardship Among New England Pediatric Stem Cell Transplant Families. *Biology of Blood and Marrow Transplantation*. 2015 Feb; 21(2):312-8. Doi: 10.1016/j.bbmt.2014.10.016. Epub 2014 Oct 23. PMID 25445021

142. Bresler SC, Weiser DA, Huwe PJ, Park JH, Krystka K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW**, Hogarty MD, **London WB**, Radhakrishnan R, Lemmon MA, Mossé YP. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. *Cancer Cell*. 2014 Nov 10; 26(5):682-94. Doi 10.1016/j.ccell.2014.09.019. Epub 2014 Nov 10. PMID: 25517749 PMCID: PMC4269829

143. Matthay KK, **London WB**, Maris J, Adamson PC, Park JR. Reply to N.K.V. Cheung et al. *J Clin Oncol.* 2014 Dec 20:32(36):4174-5. Doi: 10.1200/JCO.2014.58.7006. Epub 2014 Nov 17. PMID: 25403223.

144. Sheu J**, Hawryluk EB, Guo D**, **London WB**, Huang JT**. Voriconazole Phototoxicity in

Children: A Retrospective Review. *Journal of the American Academy of Dermatology*. 2015 Feb; 72(2):314-20. Doi: 10.1016/j.jaad.2014.10.10.023 Epub 2014 Dec 3. PMID: 25481710

145. Shulman DS**, **London WB**, Guo D**, Duncan CN, Lehmann LE. Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*. 2015 Feb 7. Pii: S1083-8791(15)00108-1. Doi: 10.1016/j.bbmt.2015.01.027. [Epub ahead of print] PMID: 25667988

146. Forester CM**, Sartain SE**, Guo D**, Harris MH, Weinberg OK, Fleming MD, **London WB**, Williams DA, Hofmann I**. Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors. *American Journal of Hematology.* 2015 Apr;90(4):320-6. Doi: 10.1002/ajh.23937. Epub 2015 Mar 2. PMID: 25580823 PMCID PMC4384448

147. Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, Lam CG, Faulkner L, Park JR, **London WB**, Matthay KK. SIOP_PODC adapted risk stratification and treatment guidelines: Recommendations for Neuroblastoma in low-and middle-income settings. *Pediatric Blood and Cancer.* 2015 Mar 21. Doi: 10.002/pbc.25501. [Epub ahead of print] PMID: 25810263.

148. Wang LL, Teshiba R, Ikegaki N, Tang XX, Naranjo A**, **London WB**, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Shimada H. Augmented Expression of MYC and/or MYCN Protein Defines Highly Aggressive MYC-Driven Neuroblastoma: A Children's Oncology Group Study. *British Journal of Cancer*. 2015 Jun 2. Doi:10.1038/bjc.2015.188. PMID: 26035700.

149. Mandriota SJ, Valentijn LJ, Lesne L, Betts, DR, Marino D, Boudal-Khoshbeen M, **London WB**, Rougemon, AL, Attiye EF, Maris JM, Hogarty MD, Koster J, Molenaar JJ, Versteeg R, Ansari M, Gumy-Pause F. Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. *Oncotarget*. 2015 May 26. PMID 26053094.

150. Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, **London WB**, Ambros PF, Nakagawara A, Berthold F, Schleiermacher G, Park JR,Valteau-Couanet D, Pearson AD, Cohn SL. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. *Journal of Clinical Oncology.* 2015 Aug 24. Pii: JCO.2014.59.4648. [Epub ahead of print] PMID: 26304901.

151. Bona K**, **London WB**, Guo D**, Frank DA, Wolfe J. Trajectory of Material Hardship and Income Poverty in Families of Children Undergoing Chemotherapy: A Prospective Cohort Study. *Pediatric Blood & Cancer*. 2015 Sept 23. Doi: 10.1002/pbc.25762. [Epub ahead of print]. PMID 26398865

152. Poorvu PD**, Barton SE, Duncan CN, **London WB**, Laufer MR, Lehmann LE, Marcus KJC. Use and effectiveness of GnRH agonists for prophylactic menstrual suppression in post-menarchal females undergoing hematopoietic cell transplantation. *J Pediatr Adolesc Gynecol*. 2015 Oct 23. PMID: 26506031.

153. Thompson D, Vo KT, **London WB**, Fischer M, Ambros PF, Nakagawara A, Brodeur GM, Matthay KK, DuBois SG. Identification of Patient Subgroups with Markedly Disparate Rates of MYCN Amplification in Neuroblastoma: A Report from the International Neuroblastoma Risk Group (INRG)

Project. *Cancer.* 2016 Mar 15;122(6):935-45. Doi: 10.1002/cncr.29848. Epub 2015 Dec 28. PMID: 26709890

154. Tubman VN**, Marshall R, Jallah W, Guo D**, Ma C**, Ohene-Frempong K, **London WB**, Heeney MM. Newborn Screening for Sickle Cell Disease in Liberia: A Pilot Study. *Pediatric Blood & Cancer.* 2016 Apr 1;63(4):671-6. Doi: 10.1002/pbc.25875. Epub 2016 Jan 6. PMID: 26739520 PubMed Central PMCID: PMC4755789

155. Ullrich CK**, Lehmann L, **London WB**, Guo D**, Sridharan M**, Koch R, Wolfe J. End-of-Life Care Patterns Associated with Pediatric Palliative Care among Children Who Underwent Hematopoietic Stem Cell Transplant. *Biol Blood Marrow Transplant*. 2016 Feb 20. Pii: S1083-8791(16)00117-8. Doi: 10.1016/j.bbmt.2016.02.012. [Epub ahead of print]. PMID: 26903381

156. Treister NS, **London WB**, Guo D**, Malsch M, Verrill K, Brewer J, Margossian S, Duncan C. A Feasibility Study Evaluating Extraoral Photobiomodulation Therapy for Prevention of Mucositis in Pediatric Hematopoietic Cell Transplantation. *Photomed Laser Surg*. 2016 Apr;34(4):178-84. Doi: 10.1089/pho.2015.4021. Epub 2016 Mar 16. PMID: 26982624

157. O'Brien R, Tran SL, Maritz MF, Liu B, Kong CF, Pugato S, Yang C, Murray J, Russell AJ, Flemming CL,von Jonquieres G, Pickett HA, **London WB,** Haber M, Gunaratne PH, Norris MD, Perini G, Fletcher JI, MacKenzie KL. MYC-Driven Neuroblastomas are Addicted to a Telomerase-Independent Function of Dyskerin. *Cancer Res.* 2016 Jun 15; 76(12):3604-17. Doi: 10.1158/0008-5472. CAN-15-0879. Epub 2016 Apr 13. PMID 27197171

158. Harris MH, DuBois SG, Glade Bender J, Kim A, Crompton BD, Parker E, Hong AL, Guo D**, Church, A, Stegmaier, K, Roberts CW, Shusterman S, **London WB**, MacConail LE, Lindeman NI, Diller L, Rodriguez-Galindo C, Janeway KA. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study. *JAMA Oncology.* 2016 Jan 28. Doi: 10.001/jamaoncol.2015.5689 [Epub ahead of print] PMID: 26822149

159. Rowe RG**, Guo D**, Lee M, Margossian S, **London WB**, Lehmann L. CMV Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection, and Cases of Recurrent and Late Infection at a Single Center. *Biol Blood Marrow Transplant*. 2016 Apr 15. Pii: S1083-8791(16)30022-2. Doi: 10.1016/j.bbmt.2016.04.004. [Epub ahead of print] PMID: 27090959

160. Morgenstern DA**, **London WB**, Stephens D, Volchenboum S, Simon T, Nakagawara A, Shimada H, Ambros PF, Matthay KK, Cohn SL, Pearson ADJ, Irwin MS. Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: a study from the International Neuroblastoma (NB) Risk Group (INRG) database. *Eur J Cancer*. 2016 Sep;65:1-10. Doi: 10.1016/j.ejca.2016.06.005. Epub 2016 Jul 17 PMID: 27434878

161. Yagyu S, Iehara T, Tanaka S, Gotoh T, Misawa-Furihata A, Sugimoto T, **London W**, Hogarty MD, Teramukai S, Nakagawara A, Hiyama E, Maris JM, Hosoi H. Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma. *PloS one*. 2016; 11(8): e0161039. PubMed PMID: 27513929

162. Xue C, Yu D M, Gherardi S, Koach J, Milazzo G, Gamble L, Liu B, Valli E, Russell AJ, **London W**, Liu T, Cheung BB, Marshall GM, Perini G, Haber M, Norris MD. MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. *Oncotarget*. 2016 Jul 19. PubMed PMID: 27448979

163. Li R**, Polishcuck A, Dubois SG, Hawkins R, Lee SW, Bagatell R, Shusterman S, Hill-Kayser C, Al-Sayegh H, Diller L, Haas-Kogan DA, Matthay K, **London WB***, Marcus KJ*. Patterns of relapse in high-risk neuroblastoma patients treated with and without total body irradiation. *International Journal of Radiation Oncology Biology Physics* 2017 Feb 1;97(2):270-277. Doi: 10.1016/j.ijrobp.2016.10.047. Epub 2016 Nov 8. PMID:28068235 (*co-senior authors)

164. von Allmen D, Davidoff AM, **London W**, Van Ryn C**, Haas-Kogan DA, Kreissman SG, Khanna G, Rosen N, Park JR, La Quaglia MP. Impact of Extent of Resection on Local Control and Survival in Patients from the COG A3973 Study with High-Risk Neuroblastoma. *Journal of Clinical Oncology* 2017 35:2, 208-216 PubMed PMID: 27870572

165. Jung M, Russell AJ, Liu B, George J, Liu PY, Liu T, DeFazio A, Bowtell DD, Oberthuer A, **London WB**, Fletcher JI, Haber M, Norris MD, Henderson MJ. A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. Cancer Res. 2017 02 15; 77(4):971-981. PMID: 27923830.

166. Applebaum MA**, Vaksman Z, Lee SM, Hungate EA, Henderson TO, **London WB**, Pinto N, Volchenboum SL, Park JR, Naranjo A**, Hero B, Pearson AD, Stranger BE, Cohn SL, Diskin SJ. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. *Eur J Cancer*. 2016 Dec 26;72:177-185. PubMed PMID: 28033528

- Audrey Evans Prize for the Outstanding Paper in Clinical Research, Advances in Neuroblastoma Research (ANR) 2016 meeting

167. Park JR, Kreissman SG, **London WB**, Naranjo A**, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Geiger JD, Doski JJ, Gorges SW, Khanna G, Voss SD, Maris JM, Grupp SA, Diller L. A phase III randomized clinical trial (RCT) of tandem myeloablative autologous stem cell transplant (ASCT) using peripheral blood stem cell (PBSC) as consolidation therapy for high-risk neuroblastoma (HR-NB): A Children's Oncology Group (COG[1]) study. *Journal of Clinical Oncology* 2016 34:18_suppl, LBA3-LBA3

168. Rubens SL**, Loucas CA, Marybeth Morris M, Manley P, Ullrich NJ, Muriel AC, Guo D**, **London WB**, Northman L**. Parent-reported outcomes associated with utilization of a pediatric cancer school consultation program. *Clin Practice in Ped Psych* 2016, Vol 4. No. 4, 383-395. Doi: 10.1037/cpp0000150.

169. Song JS**, **London WB**, Hawryluk EB, Guo D**, Sridharan M**, Fisher DE, Lehmann LE, Duncan CN, Huang JT**. Risk of melanocytic nevi and nonmelanoma skin cancer in children after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplantation* 2017 Apr 3. Doi: 10.1038/bmt.2017.57. [Epub ahead of print] PMID: 28368380

170. LaQuaglia MP, Haas-Kogan D, Park J, Kreissman SG, von Allmen D, Davidoff A, **London WB**, Khanna G. Reply to J. Stenman et al. *J Clin Oncol*. 2017 Apr 19:JCO2017722777. Doi: 10.1200/JCO.2017.72.2777. [Epub ahead of print] PMID: 28422554

171. Park JR, Bagatell R, Cohn SL, Pearson AD, Villablanca JG, Berthold F, Burchill S, Boubaker A, McHugh K, Nuchtern JG, **London WB**, Seibel NL, Lindwasser OW, Maris JM, Brock P, Schleiermacher G, Ladenstein R, Matthay KK, Valteau-Couanet D. Revisions to the International Neuroblastoma Response Criteria (INRC): A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. *Journal of Clinical Oncology.* 2017 May 4:JCO2016720177. Doi: 10.1200/JCO.2016.72.0177. [Epub ahead of print] PMID:28471719

172. Mody R, Naranjo A**, Van Ryn C**, Yu AL, **London WB**, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R. Irinotecan-temozolomide with Temsirolimus or Dinutuximab in Children with Refractory or Relapsed Neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. *Lancet Oncology* 2017 Jul;18(7):946-957. Doi: 10.1016/S1470-2045(17)30355-8. Epub 2017 May 23 PubMed PMID: 28549783; PubMed Central PMCID: PMC5527694.

173. Erbe AK, Wang W, Reville PK, Carmichael L, Kim K, Mendonca EA, Song Y, Hank JA, **London WB**, Naranjo A, Hong F, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Miller JS, Gilman AL, Kahl B, Yu AL, Sondel PM. HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome as compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-based Cancer Immunotherapy. *Frontiers in Immunology* 2017 Jun 12;8:675. Doi: 10.3389/fimmu.2017.00675. eCollection PMID: 28659916 PMCID: PMC5466980

174. Campbell K**, Gastier-Foster JM, Mann M, Naranjo AH**, Van Ryn C**, Bagatell R, Matthay KK, **London WB**, Irwin MS, Shimada H, Granger MM, Hogarty MD, Park JR, DuBois SG. Association of MYCN Copy Number with Clinical Features, Tumor Biology, and Outcomes in Neuroblastoma: A Report from the Children's Oncology Group. *Cancer* 2017 Jul 11. Doi: 10.1002/cncr.30873. [Epub ahead of print] PubMed PMID: 28696504.

175. Marinoff AE**, Ma C**, Guo D**, Snuderl M, Wright KD, Manley PE, Al-Sayegh H, Sinai CE, Ullrich NJ, Marcus K, Haas-Kogan D, Goumnerova L, **London WB**, Kieran MW, Chi SN, Fangusaro J, Bandopadhayay P. Rethinking Childhood Ependymoma: a Retrospective, Multi-center Analysis Reveals Poor Longterm Overall Survival. *J Neurooncol.* 2017 Jul 21. Doi: 10.1007/s11060-017-2568-8. [Epub ahead of print] PubMed PMID: 28733870.

176. **London WB**, Bagatell R, Weigel BJ, Fox E, Guo D**, Van Ryn C**, Naranjo A**, Park JR. Historical time to disease progression and progression-free survival in patients with relapsed/refractory neuroblastoma treated in the modern-era on Children's Oncology Group early-phase trials. *Cancer* 2017 Sep 8. Doi: 10.1002/cncr.30934. [Epub ahead of print] PMID:28885700

177. Erbe AK, Wang W, Carmichael L, Kim K, Mendonca EA, Song Y, Hess D, Reville PK, **London WB**, Naranjo A**, Hank JA, Diccianni MB, Reisfeld RA, Gillies SD, Matthay KK, Cohn SL, Hogarty MD, Maris JM, Park JR, Ozkaynak MF, Gilman A, Yu AL, Sondel PM. Neuroblastoma Patients' KIR and KIR-ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. *Clin Cancer Res*. 2017 Oct 2. Pii: clincanres.1767.2017. doi: 10.1158/1078-0432.CCR-17-1767. [Epub ahead of print] PMID:28972044

178. O'Neill AF**, Voss SD, Jagannathan JP, Kamihara J, Nibecker C, Itriago-Araujo E, Masciari S, Parker E, Barreto M, **London WB**, Garber JE, Diller L. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. *Pediatr Blood Cancer*. 2017 Oct 27. Doi: 10.1002/pbc.26822. [Epub ahead of print] PMID:29077256

179. de Alarcon PA, Matthay KK, **London WB**, Naranjo A**, Tenney SC, Panzer JA, Hogarty MD, Park JR, Maris JM, Cohn SL. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a □andomized, open-label, phase 3 trial. *Lancet Child Adolesc Health*. 2018 Jan;2(1):25-34. Doi: 10.1016/S2352-4642(17)30130-X. Epub 2017 Nov 3. PMID:29376112.

180. Ananth P**, Ma C**, Al-Sayegh H**, Kroon L, Klein V, Wharton C, Hallez E, Braun I, Michelson K, Rosenberg AR, **London W**, Wolfe J. Provider Perspectives on Use of Medical Marijuana in Children With Cancer. *Pediatrics*. 2018 Jan;141(1). Pii: e20170559. Doi: 10.1542/peds.2017-0559. Epub 2017 Dec 12. PMID:29233937.

181. Niemas-Teshiba R, Matsuno R, Wang LL, Tang XX, Chiu B, Zeki J, Coburn J, Ornell K, Naranjo A**, Van Ryn C**, **London WB**, Hogarty MD, Gastier-Foster JM, Look AT, Park JR, Maris JM, Cohn SL, Seeger RC, Asgharzadeh S, Ikegaki N, Shimada H. MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MKI neuroblastomas: a report from the children's oncology group. *Oncotarget*. 2017 Dec 15;9(5):6416-6432. Doi: 10.18632/oncotarget.23740. eCollection 2018 Jan 19. PMID:29464082.

182. Guenther LM**, Rowe RG, Acharya PT, Swenson DW, Meyer SC, Clinton CM, Guo D**, Sridharan M**, **London WB**, Grier HE, Ecklund K, Janeway KA. Response Evaluation Criteria in Solid Tumors (RECIST) following neoadjuvant chemotherapy in osteosarcoma. *Pediatr Blood Cancer*. 2018 Apr;65(4). Doi: 10.1002/pbc.26896. Epub 2017 Dec 18. PMID:29251406.

183. Grace RF**, Bianchi P, van Beers EJ, Eber SW, Glader B, Yaish HM, Despotovic JM, Rothman JA, Sharma M, McNaull MM, Fermo E, Lezon-Geyda K, Morton DH, Neufeld EJ, Chonat S, Kollmar N, Knoll CM, Kuo K, Kwiatkowski JL, Pospíšilová D, Pastore YD, Thompson AA, Newburger PE, Ravindranath Y, Wang WC, Wlodarski MW, Wang H, Holzhauer S, Breakey VR, Kunz J, Sheth S, Rose MJ, Bradeen HA, Neu N, Guo D**, Al-Sayegh H**, **London WB**, Gallagher PG, Zanella A, Barcellini W. The clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. *Blood*. 2018 Mar 16. Pii: blood-2017-10-810796. Doi: 10.1182/blood-2017-10-810796. [Epub ahead of print] PMID: 29549173

- Selected as one of the top 100 papers of 2018 by the journal *Blood*

184. Huang JT**, Song JS**, Hawryluk EB, **London WB**, Guo D**, Sridharan M**, Fisher DE, Lehmann LE, Duncan CN. Non-malignant late cutaneous changes after allogeneic hematopoietic stem cell transplant in children. *J Am Acad Dermatol*. 2018 Mar 24. Pii: S0190-9622(18)30481-X. doi: 10.1016/j.jaad.2018.03.029. [Epub ahead of print] PMID:29588248

185. Northman L**, Morris M, Loucas C, Ross S, Muriel AC, Guo D**, **London WB**, Manley P, Ullrich NJ. The Effectiveness of a Hospital-Based School Liaison Program: A Comparative Study of Parental Perception of School Supports for Children With Pediatric Cancer and Neurofibromatosis

Type 1. *J Pediatr Oncol Nurs*. 2018 Mar 1:1043454218765140. Doi: 10.1177/1043454218765140. [Epub ahead of print] PMID: 29600747

186. Heeney MM, Guo D**, De Falco L, Campagna DR, Olbina G, Kao PP**, Schmitz-Abe K, Rahimov F, Gutschow P, Westerman K, Ostland V, Jackson T, Klaassen RE, Markianos K, Finberg KE, Iolascon A, Westerman M, **London WB**, Fleming MD. Normalizing hepcidin predicts *TMPRSS6* mutation status in patients with chronic iron deficiency. *Blood*. 2018 Jun 12. Pii: blood-2017-03-773028. Doi: 10.1182/blood-2017-03-773028.

187. Ozkaynak MF, Gilman AL, **London WB**, Naranjo A**, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL. A Comprehensive Safety Trial of Chimeric Antibody 14.18 with GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. *Front Immunol*. 2018 Jun 18;9:1355. Doi: 10.3389/fimmu.2018.01355. eCollection 2018. PMC6016521.

188. Ozkaynak MF, Gilman AL, **London WB**, Naranjo A**, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL. Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931. Frontiers in immunology. 2018 Jul 16; 9: 1641. PubMed PMID: 30046297; PubMed Central PMCID: PMC6055015.

189. Shulman DS**, Klega K, Imamovic-Tuco A, Clapp A, Nag A, Thorner AR, Van Allen E, Ha G, Lessnick SL, Gorlick R, Janeway KA, Leavey PJ, Mascarenhas L, **London WB**, Vo KT, Stegmaier K, Hall D, Krailo MD, Barkauskas DA, DuBois SG, Crompton BD. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. *Br J Cancer*. 2018 Aug;119(5):615-621. Doi: 10.1038/s41416-018-0212-9. Epub 2018 Aug 21. Erratum in: Br J Cancer. 2019 Apr;120(8):869. PubMed PMID: 30131550.

190. van Beers EJ, van Straaten S, Morton DH, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kwiatkowski JL, Rothman JA, Sharma M, Neufeld EJ, Sheth S, Despotovic JM, Kollmar N, Pospíšilová D, Knoll CM, Kuo K, Pastore YD, Thompson AA, Newburger PE, Ravindranath Y, Wang WC, Wlodarski MW, Wang H, Holzhauer S, Breakey VR, Verhovsek M, Kunz J, McNaull MA, Rose MJ, Bradeen HA, Addonizio K, Li A**, Al-Sayegh H**, **London WB**, Grace RF**. Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica. 2019 Feb;104(2):e51-e53. Doi:10.3324/haematol.2018.196295. Epub 2018 Sep 13. PubMed PMID: 30213831; PubMed Central PMCID: PMC6355506.

191. Depuydt P, Boeva V, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, Asgharzadeh S, Attiyeh EF, Combaret V, Defferrari R, Fischer M, Hero B, Hogarty MD, Irwin MS, Koster J, Kreissman S, Ladenstein R, Lapouble E, Laureys G, **London WB**, Mazzocco K, Nakagawara A, Noguera R, Ohira M, Park JR, Pötschger U, Theissen J, Tonini GP, Valteau-Couanet D, Varesio L, Versteeg R, Speleman F, Maris JM, Schleiermacher G, De Preter K. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. *J Natl Cancer Inst*. 2018 Mar 5. Doi: 10.1093/jnci/djy022. [Epub ahead of print] PMID:29514301.

192. Esrick E**, Manis JP, Daley H, Baricordi C, Trébéden-Negre H, Pierciey FJ, Armant M, Nikiforow S, Heeney M, **London WB**, Biasco L, Asmal M, Williams D, Biffi A. Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients. *Blood* advances. 2018 Oct 9; 2(19): 2505-2512. PubMed PMID: 30282642; PubMed Central PMCID: PMC6177648.

193. Twist CJ, Naranjo A**, Schmidt ML, Tenney SC, Cohn SL, Meany HJ, Mattei P, Adkins ES, Shimada H, **London WB**, Park JR, Matthay KK, Maris JM. Defining Risk Factors for Chemotherapeutic Intervention in Infants with Stage 4S Neuroblastoma: A Report from Children's Oncology Group Study ANBL0531. *Journal of Clinical Oncology*. 2019 Jan 10; 37(2): 115-124. PubMed PMID: 30444686; PubMed Central PMCID: PMC6325354.

194. Morgenstern DA**, Bagatell R, Cohn SL, Hogarty MD, Maris JM, Moreno L**, Park JR, Pearson AD, Schleiermacher G, Valteau-Couanet D, **London WB***, Irwin MS*. The challenge of defining "ultra-high-risk" neuroblastoma. Pediatr Blood Cancer. 2019 Apr;66(4):e27556. Doi: 10.1002/pbc.27556. Epub 2018 Nov 26. Review. PubMed PMID: 30479064. (*share senior authorship)

195. Naranjo A**, Irwin MS, Hogarty MD, Cohn SL, Park JR, **London WB**. Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. JCO Clin Cancer Inform. 2018 Dec;2:1-15. doi: 10.1200/CCI.17.00140. PMID: 30652588; PMCID: PMC6421832.

196. Gamble LD, Purgato S, Murray J, Xiao L, Yu DMT, Hanssen KM, Giorgi FM, Carter DR, Gifford AJ, Valli E, Milazzo G, Kamili A, Mayoh C, Liu B, Eden G, Sarraf S, Allan S, Di Giacomo S, Flemming CL, Russell AJ, Cheung BB, Oberthuer A, **London WB**, Fischer M, Trahair TN, Fletcher JI, Marshall GM, Ziegler DS, Hogarty MD, Burns MR, Perini G, Norris MD, Haber M. Inhibition of polyamine synthesis and uptake reduces tumor progression and prolongs survival in mouse models of neuroblastoma. Sci Transl Med. 2019 Jan 30;11(477). Pii: eaau1099. Doi:10.1126/scitranslmed.aau1099. PubMed PMID: 30700572.

197. Pinto N, Naranjo A**, Hibbitts E, Kreissman SG, Granger MM, Irwin MS, Bagatell R, **London WB**, Greengard EG, Park JR, DuBois SG. Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG). Eur J Cancer. 2019 May;112:66-79. Doi: 10.1016/j.ejca.2019.02.003. Epub 2019 Apr 1. PubMed PMID: 30947024; PubMed Central PMCID: PMC6491235.

198. Braunstein SE, **London WB**, Kreissman SG, Villablanca JG, Davidoff AM, DeSantes K, Castleberry RP, Murray K, Diller L, Matthay K, Cohn SL, Shulkin B, von Allmen D, Parisi MT, Van Ryn C**, Park JR, La Quaglia MP, Haas-Kogan DA. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. Pediatr Blood Cancer. 2019 Apr 9:e27736. Doi: 10.1002/pbc.27736. [Epub ahead of print] PubMed PMID: 30968542.

199. Huang JT**, Coughlin CC, Hawryluk EB, Hook K, Humphrey SR, Kruse L, Lawley L, Al-Sayegh H**, **London WB**, Marghoob A, Phung TL, Pope E, Gerami P, Schmidt B, Robinson S, Bartenstein D, Bahrani E, Brahmbhatt M, Chen L, Haddock E, Mansour D, Nguyen J, Raisanen T, Tran G, Travis K, Wolner Z, Eichenfield LF. Risk Factors and Outcomes of Nonmelanoma Skin Cancer in Children

and Young Adults. J Pediatr. 2019 Aug;211:152-158. Doi: 10.1016/j.jpeds.2019.04.017. Epub 2019 May 15. PubMed PMID: 31103258.

200. Campbell K**, **Shyr D****, Bagatell R, Fischer M, Nakagawara A, Nieto AC, Brodeur GM, Matthay KK, **London WB***, DuBois SG*. Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2019 Aug;66(8):e27819. Doi: 10.1002/pbc.27819. Epub 2019 May 21. PubMed PMID: 31115156. (*share senior authorship)

201. Shusterman S, Naranjo A**, Van Ryn C**, Hank JA, Parisi MT, Shulkin BL, **London WB**, Shimada H, Gan J, Gillies SD, Maris JM, Park JR, Sondel PM, Servaes S. Anti-tumor activity and tolerability of hu14.18-IL2 with GMCSF and isotretinoin in recurrent or refractory neuroblastoma: A Children's Oncology Group phase II study. Clin Cancer Res. 2019 Jul 29. Pii: clincanres.0798.2019. doi:10.1158/1078-0432.CCR-19-0798. [Epub ahead of print] PubMed PMID: 31358541.

202. Twist CJ, Schmidt ML, Naranjo A**, **London WB**, Tenney SC, Marachelian A, Shimada H, Collins MH, Esiashvili N, Adkins ES, Mattei P, Handler M, Katzenstein H, Attiyeh E, Hogarty MD, Gastier-Foster J, Wagner E, Matthay KK, Park JR, Maris JM, Cohn SL. Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. J Clin Oncol. 2019 Aug 6:JCO1900919. Doi:10.1200/JCO.19.00919. [Epub ahead of print] PubMed PMID: 31386611.

203. Li EB**, Song JS**, Huang JT**, Hawryluk EB**, **London WB**, Guo D**, Sridharan M**, Fisher DE, Rea CJ, Lehmann LE, Duncan CN. Sun exposure and protection practices in children after allogeneic hematopoietic stem cell transplantation: A Survey-Based Cross-Sectional Cohort Study. Pediatr Dermatol. 2019 Aug 13. Doi:10.1111/pde.13984. [Epub ahead of print] PubMed PMID: 31410910.

204. Park JR, Kreissman SG, **London WB**, Naranjo A**, Cohn SL, Hogarty MD, Tenney SD, Haas-Kogan D, Shaw PJ, Kraveka JM, Roberts SS, Geiger JD, Doski JJ, Voss SD, Maris JM, Grupp SA, Diller L. Effect of Tandem Autologous Stem Cell Transplantation vs Single Transplantation on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. *JAMA* 2019. Aug 27;322(8):746-755. Doi: 10.1001/jama.2019.11642. PMID:31454045.

205. Hofmann I**, Avagyan S, Stetson A, Guo D**, Al-Sayegh H**, **London WB**, Lehmann L. Comparison of Outcomes of Myeloablative Allogeneic Stem Cell Transplantation for Pediatric Patients with Bone Marrow Failure, Myelodysplastic Syndrome and Acute Myeloid Leukemia with and without Germline GATA2 Mutations. *Biol Blood Marrow Transplant*. 2020;26(6):1124-1130. Doi:10.1016/j.bbmt.2020.02.015

206. Bianchi, P, Fermo, E, Lezon-Geyda, K, van Beers, EJ, Morton, HD, Barcellini, W, Glader, B, Chonat, S, Ravindranath, Y, Newburger, PE, Kollmar, N, Despotovic, JM, Verhovsek, M, Sharma, M, Kwiatkowski, JL, Kuo, KHM, Wlodarski, MW, Yaish, HM, Holzhauer, S, Wang, H, Kunz, J, Addonizio, K, Al-Sayegh, H**, **London, WB**, Andres, O, van Wijk, R, Gallagher, PG, Grace, RFF**. Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. *Am J Hematol*. 2020; 95: 472– 482. https://doi.org/10.1002/ajh.25753

207. Sokol E**, Desai AV**, Applebaum MA**, Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin MS, Hogarty M, Naranjo A**, Volchenboum S, Cohn SL, **London WB**. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project [published online ahead of print, 2020 Apr 21]. *J Clin Oncol*. 2020;JCO1903285. Doi:10.1200/JCO.19.03285

- Audrey Evans Prize for the Outstanding Paper in Clinical Research, Advances in Neuroblastoma Research (ANR) 2006 meeting

208. Mody R, Yu AL, Naranjo A**, Zhang FF, **London WB**, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Hank JA, Felder M, Birstler J, Sondel PM, Asgharzadeh S, Glade-Bender J, Katzenstein H, Maris JM, Park JR, Bagatell R. Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group. *J Clin Oncol*. 2020 Jul 01; 38(19):2160-2169. PMID: 32343642.

209. Al-Samkari H, Addonizio K, Glader B, Morton DH, Chonat S, Thompson AA, Kuo KHM, Ravindranath Y, Wang H, Rothman JA, Kwiatkowski JL, Kung C, Kosinski PA, Al-Sayegh H**, **London WB**, Grace RF**. The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency [published online ahead of print, 2020 May 28]. *Br J Haematol*. 2020;10.1111/bjh.16724. doi:10.1111/bjh.16724

210. Moroz V**, Machin D, Hero B, Ladenstein R, Berthold F, Kao P**, Obeng Y**, Pearson ADJ, Cohn SL, **London WB**. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG). *Pediatric Blood and Cancer* 2020 May 30. https://doi.org/10.1002/pbc.28359

211. Liu KX, Naranjo A**, Zhang FF, DuBois SG, Braunstein SE, Voss SD, Khanna G, **London WB**, Doski JJ, Geiger JD, Kreissman SG, Grupp SA, Diller LR, Park JR, Haas-Kogan DA. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol. 2020 Aug 20;38(24):2741-2752. Doi: 10.1200/JCO.19.03316. Epub 2020 Jun 12. PMID: 32530765; PMCID: PMC7430214.

212. Hawryluk EB**, Moustafa D, Bartenstein D, Brahmbhatt M, Cordoro K, Gardner L, Gauthier A, Grossman D, Gupta D, Hunt RD, Jen M, Kao PC**, Kruse LL, Lawley LP, **London WB**, Mansour D, O'Haver JA, Phung T, Pope E, Price HN, Rogers T, Shah SD, Wolner Z, Huang J**, Marghoob AA. A retrospective multicenter study of fatal pediatric melanoma. J Am Acad Dermatol. 2020 Nov;83(5):1274-1281. Doi: 10.1016/j.jaad.2020.06.1010. Epub 2020 Jul 2. PMID: 32622142.

213. Al-Samkari H, van Beers EJ, Morton DH, Barcellini W, Eber SW, Glader B, Yaish HM, Chonat S, Kuo KHM, Kollmar N, Despotovic JM, Pospíšilová D, Knoll CM, Kwiatkowski JL, Pastore YD, Thompson AA, Wlodarski MW, Ravindranath Y, Rothman JA, Wang H, Holzhauer S, Breakey VR, Verhovsek MM, Kunz J, Sheth S, Sharma M, Rose MJ, Bradeen HA, McNaull MN, Addonizio K, Al-Sayegh H**, **London WB**, Grace RF**. Characterization of the severe phenotype of pyruvate kinase deficiency. Am J Hematol. 2020 Jul 3. Doi: 10.1002/ajh.25926. Epub ahead of print. PMID: 32619047.

214. Zhong C**S, Coughlin CC, Hawryluk EB, Hook K, Humphrey SR, Kruse L, Lawley L, Kao PC**, **London WB**, Marghoob AA, Phung TL, Pope E; Skin Cancer in Children and Young Adults Consortium, Eichenfield LF, Huang JT**, Gerami P, Schmidt B, Bahrani E, Bartenstein D, Brahmbhatt M, Chen L, Haddock E, Mansour D, Nguyen J, Raisanen T, Robinson S, Rogers T, Tran G, Travis K, Wolner Z. Characteristics of non-melanoma skin cancer in children without identifiable risk factors. *J Am Acad Dermatol*. 2020 Jul 17:S0190-9622(20)32215-5. Doi: 10.1016/j.jaad.2020.07.046. Epub ahead of print. PMID: 32687967.

215. Bitterman DS**, Bona K, Laurie F, Kao PC**, Terezakis SA, **London WB**, Haas-Kogan DA. Race Disparities in Proton Radiotherapy Use for Cancer Treatment in Patients Enrolled in Children's Oncology Group Trials. JAMA Oncol. 2020 Sep 01; 6(9):1465-1468. PMID: 32910158.

216. Sokol E**, Desai AV**, Applebaum MA**, Valteau-Couanet D, Park JR, Pearson ADJ, Schleiermacher G, Irwin MS, Hogarty M, Naranjo A**, Volchenboum S, Cohn SL, **London WB**. Reply to Beiske et al. *Journal of Clinical Oncology*, 2020;38*(*31), 3720-3721. https://doi.org/10.1200/JCO.20.02147

217. Liang WH, Federico SM, **London WB**, Naranjo A**, Irwin MS, Volchenboum SL, Cohn SL. Tailoring Therapy for Children with Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. *JCO Clin Cancer Inform*. 2020 Oct;4:895-905. Doi: 10.1200/CCI.20.00074. PMID: 33058692; PMCID: PMC7608590.

218. Tao T**, Shi H, Wang M, Perez-Atayde AR, **London WB**, Gutierrez A, Lemos B, Durbin AD**, Look AT. Ganglioneuromas are driven by activated AKT and can be therapeutically targeted with mTOR inhibitors. J Exp Med. 2020 Oct 05; 217(10). PMID: 32728700

219. Wright KD, Yao X, **London WB**, Kao PC**, Gore L, Hunger S, Geyer R, Cohen KJ, Allen JC, Katzenstein HM, Smith A, Boklan J, Nazemi K, Trippett T, Karajannis M, Herzog C, Destefano J, Direnzo J, Pietrantonio J, Greenspan L, Cassidy D, Schissel D, Perentesis J, Basu M, Mizuno T, Vinks AA, Prabhu SP, Chi SN, Kieran MW. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. *Pediatr Blood Cancer*. 2020 Nov 2:e28787. Doi: 10.1002/pbc.28787. Epub ahead of print. PMID: 33140540.

220. Moreno L**, Guo D**, Irwin MS, Berthold F, Hogarty M, Kamijo T, Morgenstern D, Pasqualini C, Ash S, Potschger U, Ladenstein R, Valteau-Couanet D, Cohn SL, Pearson ADJ, **London WB**. A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. *Pediatr Blood Cancer*. 2020 Nov 18:e28794. Doi: 10.1002/pbc.28794. Epub ahead of print. PMID: 33205902. https://neuroblastoma.shinyapps.io/High-Risk-Neuroblastoma-Nomogram/

221. Esrick EB**, Lehmann LE, Biffi A, Achebe M, Brendel C, Ciuculescu MF, Daley H, MacKinnon B, Morris E, Federico A, Abriss D, Boardman K, Khelladi R, Shaw K, Negre H, Negre O, Nikiforow S, Ritz J, Pai SY, **London WB**, Dansereau C, Heeney MM, Armant M, Manis JP, Williams DA. Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. *N Engl J Med*. 2021; 384:205-215. Doi: 10.1056/NEJMoa2029392. [Epub ahead of print]

222. Yu AL, Gilman AL, Ozkaynak FM, Naranjo A**, Diccianni MB, Gan J, Hank JA, Batova A, **London WB**, Tenney SC, Smith MA, Shulkin BL, Parisi MT, Matthay KK, Cohn SL, Maris

JM, Bagatell R, Park JR, Sondel PM. Long-term follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-risk Neuroblastoma: COG Study ANBL0032. Clin Cancer Res January 27 2021 DOI**:** 10.1158/1078-0432.CCR-20-3909

223. Ma C**, Sridharan M**, Al-Sayegh H**, Li A**, Guo D**, Auclair M, Kuragayala V, Bandaru C, Milne D, Cruse H, Beaudoin R, Orechia J, Bickel J, **London WB**. Building a harmonized datamart by integrating cross-institutional systems of clinical, outcome, and genomic data: The Pediatric Patient Informatics Platform (*PPIP*). *J Clin Oncol Clinical Cancer Informatics*. 2021:5, 202-215

224. Kawano A, Hazard FK, Chiu B, Naranjo A**, LaBarre B, **London WB**, Hogarty MD, Cohn SL, Maris JM, Park JR, Gastier-Foster JM, Ikegaki N, Shimada H. Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression-A Report From the Children's Oncology Group. Am J Surg Pathol. 2020 Dec 22:10.1097/PAS.0000000000001647. doi: 10.1097/PAS.0000000000001647. Epub ahead of print. PMID: 33739795; PMCID: PMC8217390.

225. Granger MM, Naranjo A**, Bagatell R, DuBois SG, McCune JS, Tenney SC, Weiss BD, Mosse YP, Asgharzadeh S, Grupp SA, Hogarty MD, Gastier-Foster JM, Mills D, Shulkin BL, Parisi MT, **London WB**, Han-Chang J, Panoff J, von Allmen D, Jarzembowski JA, Park JR, Yanik GA. Myeloablative Busulfan/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children's Oncology Group Trial ANBL12P1. Transplant Cell Ther. 2021 Jun;27(6):490.e1-490.e8. doi: 10.1016/j.jtct.2021.03.006. Epub 2021 Mar 6. PMID: 33823167.

226. Gamble LD, Purgato S, Henderson MJ, Di Giacomo S, Russell AJ, Pigini P, Murray J, Valli E, Milazzo G, Giorgi FM, Cowley M, Ashton LJ, Bhalshankar J, Schleiermacher G, Rihani A, Van Maerken T, Vandesompele J, Speleman F, Versteeg R, Koster J, Eggert A, Noguera R, Stallings RL, Tonini GP, Fong K, Vaksman Z, Diskin SJ, Maris JM, **London WB**, Marshall GM, Ziegler DS, Hogarty MD, Perini G, Norris MD, Haber M. A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. Cancers (Basel). 2021 Apr 9;13(8):1807. Doi: 10.3390/cancers13081807. PMID: 33918978; PMCID: PMC8069650.

227. Chonat S, Eber SW, Holzhauer S, Kollmar N, Morton DH, Glader B, Neufeld EJ, Yaish HM, Rothman JA, Sharma M, Ravindranath Y, Wang H, Breakey VR, Sheth S, Bradeen HA, Al-Sayegh H**, **London WB**, Grace RF**. Pyruvate kinase deficiency in children. Pediatr Blood Cancer. 2021 Jun 14:e29148. Doi: 10.1002/pbc.29148. Epub ahead of print. PMID: 34125488.

228. Balyasny S**, Lee SM, Desai AV**, Volchenboum SL, Naranjo A**, Park JR, **London WB**, Cohn SL, Applebaum MA**. Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Netw Open. 2021 Jul 1;4(7):e2116248. Doi: 10.1001/jamanetworkopen.2021.16248. PMID: 34236408.

229. Irwin MS, Naranjo A**, Zhang FF, Cohn SL, **London WB**, Gastier-Foster JM, Ramirez NC, Pfau R, Reshmi S, Wagner E, Nuchtern J, Asgharzadeh S, Shimada H, Maris JM, Bagatell R, Park JR, Hogarty MD. Revised Neuroblastoma Risk Classification System: A Report from the Children's Oncology Group. J Clin Oncol. 2021 Jul 28:JCO2100278. Doi: 10.1200/JCO.21.00278. Epub ahead of print. PMID: 34319759.

230. Meany HJ, Widemann BC, Hinds PS, Bagatell R, Shusterman S, Stern E, Jayaprakash N, Peer CJ, Figg WD, Hall OM, Sissung TM, Kim A, Fox E, **London WB**, Rodriguez-Galindo C, Minturn JE, Dome JS. Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors. Pediatr Blood Cancer. 2021 Aug 12:e29282. Doi: 10.1002/pbc.29282. Epub ahead of print. PMID: 34383370.

231. Shimano KA, Grace RF**, Despotovic JM, Neufeld EJ, Klaassen RJ, Bennett CM, Ma C**, **London WB**, Neunert C. Phase 3 randomised trial of eltrombopag versus standard first-line pharmacological management for newly diagnosed immune thrombocytopaenia (ITP) in children: study protocol. BMJ Open. 2021 Aug 27;11(8):e044885. Doi: 10.1136/bmjopen-2020-044885. PMID: 34452956; PMCID: PMC8404450.

232. Eiduson R**, Heeney MM, Kao PC**, **London WB**, Fleming MD, Shrier LA. Prevalence and Predictors of Iron Deficiency in Adolescent and Young Adult Outpatients: Implications for Screening. Clin Pediatr (Phila). 2021 Nov 19:99228211059647. Doi: 10.1177/00099228211059647. Epub ahead of print. PMID: 34796723.

233. Yaroslavsky AN, Juliano AF, Adnan A, Selting WJ, Iorizzo TW, Carroll JD, Sonis ST, Duncan CN, **London WB**, Treister NS. Validation of a Monte Carlo Modelling Based Dosimetry of Extraoral Photobiomodulation. Diagnostics (Basel). 2021 Nov 26;11(12):2207. doi: 10.3390/diagnostics11122207. PMID: 34943447; PMCID: PMC8700113.

234. Adnan A, Yaroslavsky AN, Carroll JD, Selting W, Juliano AF, **London WB**, Sonis ST, Duncan CN, Treister NS. The Path to an Evidence-Based Treatment Protocol for Extraoral Photobiomodulation Therapy for the Prevention of Oral Mucositis. Front Oral Health. 2021 Jul 16;2:689386. doi: 10.3389/froh.2021.689386. PMID: 35048034; PMCID: PMC8757848.

235. Bezler NS**, Ilowite M*, **London WB**, Kao P**, Joffe S*, Mack JW*. Health Literacy and Clinical Outcomes Following Hematopoietic Stem-Cell Transplantation. JCO Oncol Pract. 2022 Jan 21:OP2100049. doi: 10.1200/OP.21.00049. Epub ahead of print. PMID: 35061512.

236. Severyn CJ, Siranosian BA, Kong STJ, Moreno A, Li MM, Chen N, Duncan CN, Margossian SP, Lehmann LE, Sun S, Andermann TM, Birbrayer O, Silverstein S, Kim S, Banaei N, Ritz J, Fodor AA, **London WB**, Bhatt AS, Whangbo JS. Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation. JCI Insight. 2022 Apr 8;7(7):e154344. doi: 10.1172/jci.insight.154344. PMID: 35239511.

237. Desai AV, Gilman AL, Ozkaynak MF, Naranjo A, **London WB**, Tenney SC, Diccianni M, Hank JA, Parisi MT, Shulkin BL, Smith M, Moscow JA, Shimada H, Matthay KK, Cohn SL, Maris JM, Bagatell R, Sondel PM, Park JR, Yu AL. Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. J Clin Oncol. 2022 Jul 15:JCO2102478. doi: 10.1200/JCO.21.02478. Epub ahead of print. PMID: 35839426.

238. Church AJ, Corson LB, Kao PC, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch TW, Kim A, Colace SI, Macy ME, Applebaum MA, Bagatell R, Sabnis AJ, Weiser DA, Glade-Bender JL, Homans AC, Hipps J, Harris H, Manning D, Al-Ibraheemi A, Li Y, Gupta H, Cherniack AD, Lo YC, Strand GR, Lee LA, Pinches RS, Lazo De La Vega L, Harden MV, Lennon

NJ, Choi S, Comeau H, Harris MH, Forrest SJ, Clinton CM, Crompton BD, Kamihara J, MacConaill LE, Volchenboum SL, Lindeman NI, Van Allen E, DuBois SG, **London WB**, Janeway KA. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med. 2022 Jun 23. doi: 10.1038/s41591-022-01856-6. Epub ahead of print. PMID: 35739269.

239. Connelly GG, Kirkland OO, Bohannon S, Lim DC, Wilson RM, Richards EJ, Tay DM, Jee H, Hellinger RD, Hoang NK, Hao L, Chhabra A, Martin-Alonso C, Tan EKW, Koehler AN, Yaffe MB, **London WB**, Lee PY, Krammer F, Bohannon RC, Bhatia SN, Sikes HD, Li H. Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer. Cell Rep Methods. 2022 Aug 22;2(8):100273. doi: 10.1016/j.crmeth.2022.100273. Epub 2022 Aug 4. PMID: 35942328; PMCID: PMC9350670.

240. Campbell K**, Kao PC**, Naranjo A**, Kamijo T, Ramanujachar R, **London WB***, DuBois SG*. Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer. 2022 Oct 31:e30054. doi: 10.1002/pbc.30054. Epub ahead of print. PMID: 36316811.

241. **London WB.** WANTED: Better neuroblastoma biomarkers and better stratification. *eBioMedicine.*. 2022 Dec;86:104358. doi: 10.1016/j.ebiom.2022.104358. Epub 2022 Nov 23. PMID: 36434948; PMCID: PMC9699935.

- Invited commentary

242. Eapen M, Brazauskas R, Williams DA, Walters MC, St Martin A, Jacobs BL, Antin JH, Bona K, Chaudhury S, Coleman-Cowger VH, DiFronzo NL, Esrick EB, Field JJ, Fitzhugh CD, Kanter J, Kapoor N, Kohn DB, Krishnamurti L, **London WB**, Pulsipher MA, Talib S, Thompson AA, Waller EK, Wun T, Horowitz MM. Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease. J Clin Oncol. 2023 Jan 9:JCO2201203. doi: 10.1200/JCO.22.01203. Epub ahead of print. PMID: 36623245.

243. Bender HG**, Irwin MS, Hogarty MD, Castleberry R, Maris JM, Kao PC**, Zhang FF, Naranjo A**, Cohn SL, **London WB**. Survival of neuroblastoma patients after assignment to reduced therapy due to the 12- to 18-month change in age cut-off in Children's Oncology Group (COG) risk stratification. J Clin Oncol. 2023 (in press)

Non-peer reviewed scholarship in print or other media

Book chapters

1. Kasiske BL, **London W**, Ellison MD. "Factors influencing early placement on the kidney transplant waiting list in the United States" in *Organ Allocation*. J.L Touraine (ed.) Kluwer Academic Publishers, Great Britain, 1998. 135-137.
2. Lau L, **London WB**. "Recurrent Neuroblastoma" in *Neuroblastoma – Present and Future.* H. Shimada (ed.) InTech, 2012. 29-52. Web.
3. Brumback BA, **London WB**. "Causal Inference in Cancer Clinical Trials" in *Modern Clinical Trial*

Analysis. Tang W and Tu XM (eds) Springer Science, New York, NY, 2013. 203-225.

Technical reports:

1. **London WB**, Gennings C, Edward E. (1999). A survival analysis of clusters of dependent times to event with censoring using a generalized estimating equations (GEE) approach. Technical Report Number 610, Department of Statistics, University of Florida.

Thesis

1. **London, Wendy Beth**. Application of within-cluster correlations in a generalized estimating equations (GEE) approach: Implications for inference in survival analysis. Virginia Commonwealth University, Tompkins-McCaw Library Special Collections and Archives R111.M489 1997 .L66

Abstracts, Poster Presentations and Exhibits Presented at Professional Meetings

2022

American Society of Hematology Annual Meeting

2022

American Society of Hematology Annual Meeting

2022

American Society of Hematology Annual Meeting

2022

American Society of Hematology Annual Meeting

2022 Survival of patients with neuroblastoma before versus after reduction of therapy due to the change in age cut-off from 12 to 18 months in Children's Oncology Group (COG) risk stratification (selected for oral poster discussion)
American Society of Clinical Oncology Annual Meeting

2022 Patterns of Relapse after Immunotherapy in Patients with High-Risk Neuroblastoma (selected poster)
American Society of Clinical Oncology Annual Meeting

2021 Integrating Longitudinal Clinical, Sociodemographic and Genomic Data into the National Childhood Cancer Registry (NCCR) (selected poster)
Childhood Cancer Data Initiative National Childhood Cancer Registry Data Summit

2021 Phase II Study of Nivolumab and Ipilimumab in Children and Young Adults with INI1-

Negative Cancers (selected poster)
American Society of Clinical Oncology Annual Meeting

2019 TARGET-CRM: a novel adaptive dose-escalation design for targeted therapies with applications in pediatric oncology (selected oral presentation)
Society of Clinical Trials Annual Meeting, New Orleans, LA

2019 Pyruvate Kinase (PK) Protein and Enzyme Levels in the Diagnosis and Clinical Phenotype of PK Deficiency (selected poster)
American Society of Hematology Annual Meeting

2019
(selected poster)
American Society of Hematology Annual Meeting

2019
(selected poster)
American Society of Hematology Annual Meeting

2019 Targeted sequencing in 386 patients with high-risk or recurrent / refractory pediatric extra-cranial solid malignancies: An interim report from the GAIN Consortium / iCat2 Study (selected poster)
Pediatric Cancer Working Group of the American Association for Cancer Research

2019 Prognostic Influence of Lactate Dehydrogenase & Serum Ferritin in Neuroblastoma

2019 Evaluation of the Intrinsic Hepcidin Idx™ Test to Detect Iron Deficiency in Adolescents/Young Adults (selected poster)
American Society of Pediatric Hematology and Oncology Annual Meeting

2019 Health Literacy and Patient Outcomes following Bone Marrow Transplantation (selected poster)
American Society of Pediatric Hematology and Oncology Annual Meeting

2019 Evaluation of the Intrinsic Hepcidin Idx™ Test to Detect Iron Deficiency in Adolescents/Young Adults (selected poster)
Pediatric Academic Society Annual Meeting

2016 Second malignancies in patients with neuroblastoma: a report from the International Neuroblastoma Risk Group project (Audrey Evans Prize for the Outstanding Paper in Clinical Research)
Advances in Neuroblastoma Research (ANR) 2016 Meeting

2008 A Randomized Phase 3 Trial of Myeloablative Autologous Peripheral Blood Stem Cell (PBSC) Transplant (ASCT) for High-Risk Neuroblastoma (HR-NB) Employing Immunomagnetic Purged versus Unpurged PBSC: A Children's Oncology Group (COG)

Study (Audrey Evans Prize for the Outstanding Paper in Clinical Research)
Advances in Neuroblastoma Research (ANR) 2008 Meeting

2007 Surgery and restricted use of chemotherapy as treatment of low-risk neuroblastoma: Preliminary results of Children's Oncology Group protocol 9641 ("Best of SIOP" Award Lecture)
American Society of Pediatric Hematology/Oncology (ASPHO)

2006 Surgery and restricted use of chemotherapy as treatment of low-risk neuroblastoma: Preliminary results of Children's Oncology Group protocol 9641 (Winner of "Best Clinical Trials" presentation)
38th Congress of the International Society of Paediatric Oncology

2006 Age, Tumor Grade, and Mitosis-Karyorrhexis Index are Independently Predictive of Outcome in Neuroblastoma (Best Clinical Science Poster)
University of Florida College of Medicine Research Day

2006 Age, Tumor Grade, and MKI Are Independently Predictive of Outcome in Neuroblastoma (Audrey Evans Prize for the Outstanding Paper in Clinical Research)
Advances in Neuroblastoma Research (ANR) 2006 Meeting

1990 Teaching the SAS programming language to programmers and non-programmers ("Best Contributed Paper" in the section Education, Consulting, and Technical Support)
SAS Users Group International 15th Annual Conference

1989 Standard operating procedure in the creation, maintenance, and quality assurance of SAS programs ("Honorable Mention" in the section on in Education, Consulting, and Technical Support)
SAS Users Group International 14th Annual Conference

Narrative Report

I am a biostatistician, a teacher, a mentor, a leader, an administrator, a scientist. Team science:

Above and beyond team science, I lead independent research as a NB scientist; I am the world's leading expert in the identification and application of NB prognostic factors to determine treatment intensity. My NB research program has been conducted in my dry lab; I have mentored dozens of clinical investigators in successful publication of research and career development. My unique combination of expertise in NB and in biostatistics is synergistic; few others, if any, could develop the innovations in NB risk/treatment stratification that I have. My area of excellence is Investigation, with interdisciplinary expertise in biostatistics, pediatric solid tumors and blood disorders, leadership in clinical trials, and advancements in NB.

Early career - I played an instrumental role (1987-92) in the success of CRO start-up I trained at Virginia Commonwealth University's Medical College of Virginia while working at the United Network for Organ Sharing (UNOS). My interests in survival analysis and cancer led to a faculty position as a biostatistician in the Children's Oncology Group [COG[1]], an NIH/NCI cancer cooperative group, at the University of Florida's COG Statistics and Data Center. Thereafter, my research career evolved to a focus in NB.

NB Risk stratification research and impact - I am the world's leading statistical expert in NB risk stratification. My dry lab research has accurately identified which children need more/different therapy to survive, and who can survive/thrive with less/no therapy [33,34,37,38,43,51,53,56,59,60,66,68,71,80,86,92,94,97,100,114,127,133,136, 137,138,153,160,174,194,200,207,210,216,220]. I identified an optimal 547-day (18-month) age cut-off to differentiate younger (better outcome) from older (worse outcome) patients [34,243]. We reached international consensus to change the age cut-off from 12 months to 18 months. COG[1] instituted a new standard of care for two subgroups of toddlers 12-18 months old at diagnosis: (INSS stage 4, favorable *MYCN*, INPC, and ploidy) and (INSS stage 3, *MYCN* not amplified, unfavorable INPC). Due to the age cut-off change, these patients received a reduction of therapy from intensive multi-modality including stem cell transplant, to response-adaptive chemotherapy, resulting in less treatment-related toxicity. The 18-month age cut-off was used in the new International Neuroblastoma Risk Group Staging System (INRGSS) [56]. As the Chair of the International Neuroblastoma Risk Group (INRG) Statistics Committee, I have scientific oversight for the INRG Data Commons (>24,000 patients), and review/approve national and international proposals for data analyses.

I have a unique perspective and skill set, a hybridization of expertise in NB and statistical methodology. Dr. Lucas Moreno and I developed a nomogram to identify an "ultra-high-risk" cohort [220] https://neuroblastoma.shinyapps.io/High-Risk-Neuroblastoma-Nomogram/, utilized by the Global Neuroblastoma Network (coordinated by St. Jude Children's Research Hospital). Next, my dry lab research seeks improvement in high-risk NB stratification. My mentee, Dr. Moreno (PI), and I (Co-PI) were awarded a 3-year grant from Solving Kids' Cancer to identify children with the highest chance of dying from their NB, to offer experimental therapy instead of standard of care at diagnosis. (Without a government funding system, preeminent European foundations like Solving Kids' Cancer use a rigorous NIH-like peer-review process to award funding.)

Clinical trials: design, conduct, and impact - The COG[1] is an NIH/NCI funded infrastructure for the conduct of trials that set the standard of care for children with cancer; COG is not a professional society. Unlike committees for societies, COG[1] committees are scientific working groups that design and conduct clinical trials, with a separate 'committee' for each disease. Appointment to a COG[1] committee as the biostatistician carries a greater level of national prominence than election to a national society. I was 95-100% funded by the NIH/NCI to perform research on COG[1] trials from 1998-2009, decreasing to 30% (2009-2014) when I moved to DFCI/BCH. During my tenure as a COG[1] statistician, our NB clinical trials resulted in dramatic improvements in outcome: 3-year overall survival for high-risk NB increased from ~30% in 1998 to >60% in 2019. Over two decades, I designed and conducted phase 2 and 3 trials that set new standards of care: FDA approval of dinutuximab after transplant in high-risk NB [75,82] (ANR[2] plenary 2010); tandem transplant for high-risk NB [204] (American Society of Clinical Oncology [ASCO] plenary 2016); expectant observation for infants <6 months old [116]; reduction of chemotherapy in intermediate-risk NB [81,202]; emergent therapy for symptomatic intermediate-risk NB [193]; topotecan plus cyclophosphamide for relapsed/refractory [79] and newly diagnosed NB [99]; and, intravenous immunoglobulin for opsoclonus myoclonus ataxia syndrome [179]. I have been the statistician for key NB biomarkers, including ALK for targeted therapy (crizotanib) [53,92,142], 1p and 11q LOH [39], ODC1 [57], *MYCN* expression [11], and the genetic landscape of high-risk NB [120]. In addition, I led the efforts to describe progression-free survival in a large historical cohort of relapsed/refractory NB [176], providing a historical basis to which experimental therapies can be compared in future national/international phase 2 trials. I served as statistician on landmark trials for gene therapy for X-Linked Severe Combined Immunodeficiency [139], secondary malignancies in pediatric Hodgkin disease [49], outcome/staging/treatment of malignant germ cell tumors [19,20,22], NUT midline carcinoma [110], the kidney transplant waiting list [5], and response-based treatment for intermediate/high-risk Hodgkin disease [70].

International reputation in NB clinical research - I received invitations to present the landmark results of our randomized trial of dinutuximab at the University of Cologne (2009), Royal Marsden (2009) and the International Society of Pediatric Oncology (Sao Paolo, Brazil, 2009). Drs. Frank Berthold (University of Cologne) and Lothar Krempel (Max Planck Institute for the Study of Societies) conducted an analysis entitled, "The development of the ANR[2] (Advances in Neuroblastoma Research) network: A study of the contributions 1975-2015". Of 7,787 authors /investigators worldwide, I ranked 11th in the number of ANR[2] abstracts. My H-indices are 88 (Google Scholar) and

66 (Web of Science), my i10-index is 214, and my publications have been cited 29,429 times (Google Scholar) or 17,610 (Web of Science), a large number given the rarity of NB.

COG[1] NB Virtual Tumor Bank development - I conceived and designed the COG[1]'s NB Virtual Tumor Bank (NVTB) database, linking clinical, biological, outcomes, and specimen data for COG[1] and international contributors. My foresight to require submission of outcome data on COG[1] NB biology studies laid the groundwork for two decades of fruitful genetic biomarker research that would otherwise have not been possible. Scientists use the NVTB for national and international basic science projects, including Dr. John Maris' [38,46,64,69,88,118,120], and Dr. Michelle Haber's labs [11,28,42,57,95,103,135,157,162,165,196,226].

Impact of statistical methodology development - I developed new methods for stratified Phase 2 designs [35], utilized for design and conduct of at least eight national multi-center NIH/NCI oncology phase 2 clinical trials of small, heterogeneous cohorts. I developed the statistical framework for the national COG[1] and international INRG risk stratifications; one approach used a novel finite mixture survival model [63]. I am mentoring Dr. Arlene Naranjo in creating the new COG[1] NB risk stratification [195]. Under my mentorship, Dr. Clement Ma and I have developed new methods for novel adaptive phase 1 trial designs to favor accrual within rare genomic subgroups (manuscript submitted). I am the statistician for four adaptive-design phase 1 trials currently underway at DFCI/BCH; adaptive phase 1 designs are a groundbreaking approach in pediatric oncology. Dr. Ma and I have developed the DEDUCE application for design and conduct of adaptive trials by a statistician-clinician duo; this soon-to-be-released application will be open-source, available to scientists worldwide.

Mentoring and teaching - I have mentored >100 fellows and junior faculty in COG[1], BCH, DFCI, and elsewhere; many have advanced to leadership roles or published landmark papers (see "Other Mentored Trainees and Faculty"). I have mentored five biostatistics graduate students, including two at Harvard School of Public Health. I mentored junior faculty on K awards (including Dr. David Shulman), and my first Wellesley College intern attends the University of Michigan medical school. I am an invited faculty member at the annual American Association for Cancer Research (AACR)/ASCO Methods in Clinical Cancer Research workshop in Vail, Colorado (plenary lecture on correlative studies). I lecture on clinical trials and statistics to hem/onc fellows, clinicians and COG[1] members, some for CME credit. I have taught >20 oncologists in our Global Health Initiative. In my dry lab, I have mentored dozens of clinicians on NB clinical research projects, with successful manuscript publications. An integral component of my teaching occurs daily, in one-on-one sessions with clinician-scientists for specific trials.

National service - I have served as a permanent member on the NIH's Clinical Oncology (CONC) Study Section and Therapeutic Immune Regulation (TIR) Study Section (R01/R21), ad-hoc on Subcommittee H (peer review of NIH/NCI Cancer Cooperative Groups) and NIH's Cancer Biomarker Study Section. I am on the editorial board of the *Journal of the National Cancer Institute* (impact factor: 12.6) and the AACR Clinical Trials Committee. I served on the editorial board of the *Journal of Clinical Oncology* (impact factor: 44.54), ASCO Program Committee, and as an assistant editor for Medical and Pediatric Oncology.

Local administrative and informatics accomplishments - My Significant Supporting Activity is Administrative and Institutional Service. I led the University of Florida's COG[1] Statistics and Data Center while transitioning to electronic data capture, managing five PhD statisticians and 20 staff (~$2M annual budget). At DFCI/BHC, I built two new programs: the Biostatistics Program, and the Clinical and Translational Investigation Program (CTIP) to provide infrastructure for clinical research. CTIP is a model for clinical research infrastructure at BCH, growing from 15 to >60 staff and supporting seven disease programs during my 10-year tenure. The Biostatistics Program has a self-sustaining funding model. My infrastructure and training grant from Alex's Lemonade Stand Foundation (Multi-PI: London and Dubois) supports clinical research staff and protected time for junior faculty. To address a critical need to integrate and harmonize data between BCH and DFCI for efficient and reproducible analyses, I created the Pediatric Patient Informatics Platform (*PPIP*) [223], a datamart harmonizing 14 source databases: 2,622 data items/33,674 patients/3.6 million visits. *PPIP* contributes data to DFCI's PRISSMM project, the National Childhood Cancer Registry, Massachusetts Cancer Registry, and internationally via NIH/AACR's Project GENIE. I

am the Director for the DF/HCC Survey and Qualitative Methods Core (2014-present) and I have served on multiple institutional committees.

I take great pleasure and pride in the complimentary/interdisciplinary aspects of my research and teaching. It is a privilege to contribute to world class team science for pediatric cancers and blood disorders. Using my biostatistical and neuroblastoma expertise, I will continue work in my dry lab to advance my research program to improve treatment and outcome for children with neuroblastoma.